10 completed, 4 terminated, 2 unknown, 2 withdrawn. 19 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 19 | Completed 10, Terminated 4, Unknown 2, Withdrawn 2, Active not recruiting 1 |
Follow Natalizumab: new trials by email Literature Review of Natalizumab trials Research Report on Natalizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Natalizumab - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Terminated | Biogen | 1 | 2023-01-23 | 2024-06-21 |
| Natalizumab and Chronic Inflammation Natalizumab 300 MG in 15 ML Injection - Multiple Sclerosis | Phase 4 | Terminated | Vanderbilt University Medical Center | 1 | 2022-09-16 | 2024-04-18 |
| Methylprednisolone During the Switch Between Natalizumab and Fingolimod Methylprednisolone, Placebo, natalizumab (NTZ) - Multiple Sclerosis | Phase 4 | Unknown | University Hospital, Clermont-Ferrand | 56 | 2019-06-12 | 2023-01-09 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
| Towards Personalized Dosing of Natalizumab in Multiple Sclerosis Natalizumab - Multiple Sclerosis | Phase 4 | Completed | Amsterdam UMC, location VUmc | 61 | 2016-11-03 | 2019-07-12 |
| Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis Natalizumab - Multiple Sclerosis | Phase 4 | Completed | State University of New York at Buffalo | 30 | 2015-08-01 | 2025-01-24 |
| Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants natalizumab, fingolimod - Relapsing-Remitting Multiple Sclerosis | Phase 4 | Terminated | Biogen | 111 | 2014-11-30 | 2017-06-09 |
| Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies natalizumab - Relapsing Multiple Sclerosis | Phase 4 | Terminated | Biogen | 47 | 2014-09-30 | 2017-06-05 |
| Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Fingolimod, Natalizumab - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | University Hospital Muenster | 15 | 2014-03-01 | 2014-12-25 |
| Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) BG00002 - Relapsing-Remitting Multiple Sclerosis | Phase 4 | Completed | Biogen | 100 | 2012-05-01 | 2014-05-20 |
| NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness Natalizumab (Tysabri) - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Completed | Cornerstone Health Care, PA | 37 | 2012-03-01 | 2014-01-29 |
| Natalizumab De-escalation With Interferon Beta-1b interferon beta-1b, Natalizumab - Relapsing-remitting Multiple Sclerosis | Phase 4 | Completed | Claudio Gobbi | 19 | 2010-06-01 | 2014-04-17 |
| A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients BG00002 (natalizumab) - Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 4 | Completed | Biogen | 224 | 2009-08-01 | 2017-03-21 |
| Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment Natalizumab - Multiple Sclerosis | Phase 4 | Completed | University Hospital, Toulouse | 300 | 2009-06-01 | 2011-03-30 |
| Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy natalizumab - Crohn's Disease | Phase 4 | Withdrawn | Biogen | 2008-12-01 | 2016-06-16 | |
| A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a TYSABRI and AVONEX - Relapsing-remitting Multiple Sclerosis | Phase 4 | Withdrawn | Biogen | 2008-11-01 | 2024-06-03 | |
| A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State Natalizumab - Multiple Sclerosis | Phase 4 | Completed | Biogen | 20 | 2008-11-01 | 2015-02-10 |
| The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td) - Multiple Sclerosis | Phase 4 | Completed | Biogen | 60 | 2008-01-01 | 2017-02-15 |
| Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease natalizumab - Crohn's Disease | Phase 4 | Completed | Biogen | 2000 | 2002-07-01 | 2016-06-16 |
Multiple Sclerosis, Relapsing-Remitting (9) · Multiple Sclerosis (7) · Crohn Disease (2)
Biogen (10) · Amsterdam UMC, location VUmc (1) · Claudio Gobbi (1) · Cornerstone Health Care, PA (1) · State University of New York at Buffalo (1) · The Cleveland Clinic (1) · University Hospital Muenster (1) · University Hospital, Clermont-Ferrand (1) · University Hospital, Toulouse (1) · Vanderbilt University Medical Center (1)
United States (9) · France (3) · Germany (3) · United Kingdom (2) · Australia (1) · Belgium (1) · Czechia (1) · Italy (1) · Mexico (1) · Netherlands (1) · Poland (1) · Romania (1) · Russia (1) · Saudi Arabia (1) · Spain (1)
Bianca Weinstock-Guttman, MD (1) · Claudio Gobbi, Dr med. (1) · Daniel Ontaneda, MD, MSc (1) · David Brassat, MD, PhD (1) · Francesca Bagnato, MDPhD (1) · Joep Killestein, Dr. (1) · Luisa Klotz, PD. Dr. med. (1) · Nikos Evangelou, MD, DPhil (1) · Richard A Sater, MD, PhD (1)
PMID 23915113, PMID 24576156, PMID 30050529, PMID 33082194, PMID 42218617
2015 (1)